Shu-Ichi Kanazashi, Ph.D., M.D., was elected the Managing Executive Officer and Chief Medical Officer of SNBL in June 2016. He has served as TR Company President since 2014 and as the director of SNLD Inc. since 2019. Prior to joining SNBL, Dr. Kanazashi was the Chief Executive Officer of UMN Pharma Inc. (Tokyo and Connecticut, US, 2006). Previously, he was employed by Nippon Roche K.K. (Tokyo and Basel, CH, 2000) and Sony Corporation (Tokyo and Oxford, UK, 2002) as the Medical Scientist, where he engaged in research and development of recombinant Flu vaccines and “Tamiflu”, as well as genomic SNP detection followed by DNA chip production.
As a diplomate of the Japan Pediatric Society and the Japanese Society of Allergology, he was engaged in clinical practice at various hospitals in Japan and accumulated abundant clinical experience. Dr. Kanazashi received his M.D. in 1986 from Kyoto University and in 1994 he received his Ph.D. degree in Medical Science from the Graduate School of Kyoto University. He completed his research fellowship at Harvard Medical School/ Massachusetts General Hospital from 1995 to 1998.